Eisai's Perampanel Shows Positive Phase III Results For Epilepsy Following Failure As Parkinson's Treatment
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Positive Phase III results in epilepsy for the AMPA receptor antagonoist perampanel set it on a rebound following Eisai's decision two years ago to abandon development of the drug in Parkinson's disease
You may also be interested in...
Eisai Drops Perampanel In Parkinson’s, Plans First Neuropathy Submission For 2010
Eisai announced April 11 it has abandoned development of its novel AMPA receptor antagonist perampanel in Parkinson's disease after a second Phase III trial failed, but the Tokyo firm is forging ahead with the compound in other neurological indications
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).